158 related articles for article (PubMed ID: 38180746)
1. MAGE-A11 is a potential prognostic biomarker and immunotherapeutic target in gastric cancer.
Wang ZW; Yu QY; Xu MJ; Zhou CY; Li JP; Liao XH
Aging (Albany NY); 2024 Jan; 16(1):285-298. PubMed ID: 38180746
[TBL] [Abstract][Full Text] [Related]
2. MAGE-A family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients.
Lian Y; Sang M; Gu L; Liu F; Yin D; Liu S; Huang W; Wu Y; Shan B
Pathol Res Pract; 2017 Aug; 213(8):943-948. PubMed ID: 28647208
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Significance of MAGE-A11 in Esophageal Squamous Cell Carcinoma and Identification of Related Genes Based on DNA Microarray.
Sang M; Gu L; Liu F; Lian Y; Yin D; Fan X; Ding C; Huang W; Liu S; Shan B
Arch Med Res; 2016 Apr; 47(3):151-61. PubMed ID: 27362547
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma.
Wu Y; Sang M; Liu F; Zhang J; Li W; Li Z; Gu L; Zheng Y; Li J; Shan B
Carcinogenesis; 2020 Jul; 41(7):894-903. PubMed ID: 32529260
[TBL] [Abstract][Full Text] [Related]
5. Expression of MAGE-A11 in breast cancer tissues and its effects on the proliferation of breast cancer cells.
Xia LP; Xu M; Chen Y; Shao WW
Mol Med Rep; 2013 Jan; 7(1):254-8. PubMed ID: 23064813
[TBL] [Abstract][Full Text] [Related]
6. Zebularine Treatment Induces MAGE-A11 Expression and Improves CTL Cytotoxicity Using a Novel Identified HLA-A2-restricted MAGE-A11 Peptide.
Zhang J; Sang M; Gu L; Liu F; Li W; Yin D; Wu Y; Liu S; Huang W; Shan B
J Immunother; 2017; 40(6):211-220. PubMed ID: 28486273
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of cancer-testis antigens of MAGE-A6 and MAGE-A11 is associated with tumor aggressiveness in patients with bladder cancer.
Mohsenzadegan M; Razmi M; Vafaei S; Abolhasani M; Madjd Z; Saeednejad Zanjani L; Sharifi L
Sci Rep; 2022 Jan; 12(1):599. PubMed ID: 35022469
[TBL] [Abstract][Full Text] [Related]
8. The Expression of Melanoma-Associated Antigen D2 Both in Surgically Resected and Serum Samples Serves as Clinically Relevant Biomarker of Gastric Cancer Progression.
Kanda M; Nomoto S; Oya H; Takami H; Shimizu D; Hibino S; Hashimoto R; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
Ann Surg Oncol; 2016 Feb; 23 Suppl 2():S214-21. PubMed ID: 25743330
[TBL] [Abstract][Full Text] [Related]
9. Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: a retrospective clinical study.
Lian Y; Sang M; Ding C; Zhou X; Fan X; Xu Y; Lü W; Shan B
J Cancer Res Clin Oncol; 2012 Mar; 138(3):519-27. PubMed ID: 22198676
[TBL] [Abstract][Full Text] [Related]
10. Research progress in effects of MAGE-A family on gastric cancer.
Jia Q; Xian X; Li Y; Mu J; DU Z
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Feb; 48(2):260-267. PubMed ID: 36999473
[TBL] [Abstract][Full Text] [Related]
11. Proto-oncogene activity of melanoma antigen-A11 (MAGE-A11) regulates retinoblastoma-related p107 and E2F1 proteins.
Su S; Minges JT; Grossman G; Blackwelder AJ; Mohler JL; Wilson EM
J Biol Chem; 2013 Aug; 288(34):24809-24. PubMed ID: 23853093
[TBL] [Abstract][Full Text] [Related]
12. Melanoma associated antigen (MAGE)-A3 promotes cell proliferation and chemotherapeutic drug resistance in gastric cancer.
Xie C; Subhash VV; Datta A; Liem N; Tan SH; Yeo MS; Tan WL; Koh V; Yan FL; Wong FY; Wong WK; So J; Tan IB; Padmanabhan N; Yap CT; Tan P; Goh LK; Yong WP
Cell Oncol (Dordr); 2016 Apr; 39(2):175-86. PubMed ID: 26868260
[TBL] [Abstract][Full Text] [Related]
13. Expression and prognostic significance of MAGE-A11 and transcription factors (SP1,TFCP2 and ZEB1) in ESCC tissues.
Gu L; Sang M; Li J; Liu F; Wu Y; Liu S; Wang P; Shan B
Pathol Res Pract; 2019 Jul; 215(7):152446. PubMed ID: 31126819
[TBL] [Abstract][Full Text] [Related]
14. Expression of MAGE-A1, -A9, -A11 in laryngeal squamous cell carcinoma and their prognostic significance: a retrospective clinical study.
Liu S; Sang M; Xu Y; Gu L; Liu F; Shan B
Acta Otolaryngol; 2016; 136(5):506-13. PubMed ID: 26766421
[TBL] [Abstract][Full Text] [Related]
15. Expressions of MAGE-A9 and MAGE-A11 in breast cancer and their expression mechanism.
Hou SY; Sang MX; Geng CZ; Liu WH; Lü WH; Xu YY; Shan BE
Arch Med Res; 2014 Jan; 45(1):44-51. PubMed ID: 24316396
[TBL] [Abstract][Full Text] [Related]
16. The therapeutic potential value of Cancer-testis antigens in immunotherapy of gastric cancer.
Alsadat Mahmoudian R; Amirhosein M; Mahmoudian P; Fardi Golyan F; Mokhlessi L; Maftooh M; Khazaei M; Nassiri M; Mahdi Hassanian S; Ghayour-Mobarhan M; Ferns GA; Shahidsales S; Avan A
Gene; 2023 Feb; 853():147082. PubMed ID: 36464170
[TBL] [Abstract][Full Text] [Related]
17. Post-translational Down-regulation of Melanoma Antigen-A11 (MAGE-A11) by Human p14-ARF Tumor Suppressor.
Minges JT; Grossman G; Zhang P; Kafri T; Wilson EM
J Biol Chem; 2015 Oct; 290(41):25174-87. PubMed ID: 26330556
[TBL] [Abstract][Full Text] [Related]
18. MAGE-A11 expression contributes to cisplatin resistance in head and neck cancer.
Hartmann S; Zwick L; Scheurer MJJ; Fuchs AR; Brands RC; Seher A; Böhm H; Kübler AC; Müller-Richter UDA
Clin Oral Investig; 2018 Apr; 22(3):1477-1486. PubMed ID: 29034444
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of MAGE-D4 in colorectal cancer is a potentially prognostic biomarker and immunotherapy target.
Zhang QM; He SJ; Shen N; Luo B; Fan R; Fu J; Luo GR; Zhou SF; Xiao SW; Xie XX
Int J Clin Exp Pathol; 2014; 7(7):3918-27. PubMed ID: 25120768
[TBL] [Abstract][Full Text] [Related]
20. Demethylation-mediated upregulation of melanoma-associated antigen-A11 correlates with malignant progression of esophageal squamous cell carcinoma.
Gu L; Sang M; Li J; Liu F; Wu Y; Liu S; Shan B
Dig Liver Dis; 2019 Oct; 51(10):1475-1482. PubMed ID: 31155488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
